Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy

被引:249
|
作者
Frangogiannis, Nikolaos G.
Dewald, Oliver
Xia, Ying
Ren, Guofeng
Haudek, Sandra
Leucker, Thorsten
Kraemer, Daniela
Taffet, George
Rollins, Barrett J.
Entman, Mark L.
机构
[1] Baylor Coll Med, Methodist Hosp, Cardiovasc Sci Sect, Houston, TX 77030 USA
[2] Baylor Coll Med, Methodist Hosp, DeBakey Heart Ctr, Houston, TX 77030 USA
[3] Univ Bonn, Dept Cardiac Surg, D-5300 Bonn, Germany
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
关键词
inflammation; ischemia; reperfusion; immunology; pathology; fibrosis; cardiomyopathy;
D O I
10.1161/CIRCULATIONAHA.106.646091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Cardiac interstitial fibrosis plays an important role in the pathogenesis of ischemic cardiomyopathy, contributing to systolic and diastolic dysfunction. We have recently developed a mouse model of fibrotic noninfarctive cardiomyopathy due to brief repetitive myocardial ischemia and reperfusion. In this model, fibrotic changes are preceded by marked and selective induction of the CC chemokine monocyte chemoattractant protein-1 (MCP-1). We hypothesized that MCP-1 may mediate fibrotic remodeling through recruitment of mononuclear cells and direct effects on fibroblasts. Methods and Results - Wild-type (WT) and MCP-1-null mice underwent daily 15-minute coronary occlusions followed by reperfusion. Additional WT animals received intraperitoneal injections of a neutralizing anti-MCP-1 antibody after the end of each ischemic episode. Hearts were examined echocardiographically and processed for histological and RNA studies. WT mice undergoing repetitive brief myocardial ischemia and reperfusion protocols exhibited macrophage infiltration after 3 to 5 days and marked interstitial fibrosis in the ischemic area after 7 days, accompanied by ventricular dysfunction. MCP-1-null mice had markedly diminished interstitial fibrosis, lower macrophage infiltration, and attenuated ventricular dysfunction compared with WT animals. MCP-1 neutralization also inhibited interstitial fibrosis, decreasing left ventricular dysfunction and regional hypocontractility. Cardiac myofibroblasts isolated from WT but not from MCP-1-null animals undergoing repetitive myocardial ischemia and reperfusion demonstrated enhanced proliferative capacity. However, MCP-1 stimulation did not induce cardiac myofibroblast proliferation and did not alter expression of fibrosis-associated genes. Conclusions - Defective MCP-1 signaling inhibits the development of ischemic fibrotic cardiomyopathy in mice. The profibrotic actions of MCP-1 are associated with decreased macrophage recruitment and may not involve direct effects on cardiac fibroblasts.
引用
收藏
页码:584 / 592
页数:9
相关论文
共 50 条
  • [31] Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy
    Banba, N
    Nakamura, T
    Matsumura, M
    Kuroda, H
    Hattori, Y
    Kasai, K
    KIDNEY INTERNATIONAL, 2000, 58 (02) : 684 - 690
  • [32] Hypoxic-ischemic injury induces monocyte chemoattractant protein-1 expression in neonatal rat brain
    Ivacko, J
    Szaflarski, J
    Malinak, C
    Flory, C
    Warren, JS
    Silverstein, FS
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1997, 17 (07) : 759 - 770
  • [33] Human LZIP induces monocyte CC chemokine receptor 2 expression leading to enhancement of monocyte chemoattractant protein 1/CCL2-induced cell migration
    Ho Joong Sung
    Yoon Suk Kim
    Hyereen Kang
    Jesang Ko
    Experimental & Molecular Medicine, 2008, 40 : 332 - 338
  • [34] Human LZIP induces monocyte CC chemokine receptor 2 expression leading to enhancement of monocyte chemoattractant protein 1/CCL2-induced cell migration
    Sung, Ho Joong
    Kim, Yoon Suk
    Kang, Hyereen
    Ko, Jesang
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2008, 40 (03) : 332 - 338
  • [35] Effect of CC Chemokine Receptor 2 CCR2 Blockade on Serum C-Reactive Protein in Individuals at Atherosclerotic Risk and With a Single Nucleotide Polymorphism of the Monocyte Chemoattractant Protein-1 Promoter Region
    Gilbert, Jim
    Lekstrom-Himes, Julie
    Donaldson, Debra
    Lee, Yih
    Hu, Mingxiu
    Xu, Jing
    Wyant, Tim
    Davidson, Michael
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (06) : 906 - 911
  • [36] Monocyte chemoattractant protein-1 induces monocyte recruitment that is associated with an increase in numbers of osteoblasts
    Posner, LJ
    Miligkos, T
    Gilles, JA
    Carnes, DL
    Taddeo, DR
    Graves, DT
    BONE, 1997, 21 (04) : 321 - 327
  • [37] Genetically Determined Levels of Circulating Cytokines and Risk of Stroke: Role of Monocyte Chemoattractant Protein-1
    Georgakis, Marios K.
    Gill, Dipender
    Rannikmaee, Kristiina
    Traylor, Matthew
    Anderson, Christopher D.
    Lee, Jin-Moo
    Kamatani, Yoichiro
    Hopewell, Jemma C.
    Worrall, Bradford B.
    Bernhagen, Juergen
    Sudlow, Cathie L. M.
    Malik, Rainer
    Dichgans, Martin
    CIRCULATION, 2019, 139 (02) : 256 - 268
  • [38] Is there a role for monocyte chemoattractant protein-1 in delirium? Novel observations in elderly hip fracture patients
    Skrede K.
    Wyller T.B.
    Watne L.O.
    Seljeflot I.
    Juliebø V.
    BMC Research Notes, 8 (1)
  • [39] The Therapeutic Role of Monocyte Chemoattractant Protein-1 in a Renal Tissue Engineering Strategy for Diabetic Patients
    Yin, Hao
    Gao, Ming
    Leoni, Lara
    Han, Huifang
    Zhang, Xing
    Fu, Zhiren
    PLOS ONE, 2013, 8 (02):
  • [40] Circulating Monocyte Chemoattractant Protein-1 (MCP-1) in Patients with Primary Biliary Cholangitis
    Bauer, Alicja
    Rawa, Tomasz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (02)